RECTAS | CAS#101862-47-9 | IKBKAP splicing modulator

MedKoo Cat#: 466262 | Name: RECTAS

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RECTAS (rectifier of aberrant splicing) is a splicing modulator of the IKBKAP (inhibitor of κ light polypeptide gene enhancer in B-cells, kinase complex associated protein) gene. It corrects aberrant IKBKAP splicing in vitro in cellular models of familial dysautonomia and in vivo, in transgenic mice. RECTAS can induce the production of splice-neoantigens that could be used to boost antitumor immune responses. RECTAS directly interacts with CDC-like kinases (CLKs) and enhances SRSF6 phosphorylation.

Chemical Structure

RECTAS

CAS#101862-47-9

Theoretical Analysis

MedKoo Cat#: 466262

Name: RECTAS

CAS#: 101862-47-9

Chemical Formula: C10H8ClN5O

Exact Mass: 249.0417

Molecular Weight: 249.66

Elemental Analysis: C, 48.11; H, 3.23; Cl, 14.20; N, 28.05; O, 6.41

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 340.00	2 Weeks
50mg	USD 960.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

RECTAS;

IUPAC/Chemical Name

2-chloro-N-(furan-2-ylmethyl)-7H-purin-6-amine

InChi Key

QGUOPVCOXHVPJX-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H8ClN5O/c11-10-15-8(7-9(16-10)14-5-13-7)12-4-6-2-1-3-17-6/h1-3,5H,4H2,(H2,12,13,14,15,16)

SMILES Code

ClC1=NC2=C(C(NCC3=CC=CO3)=N1)NC=N2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMSO	25.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 249.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matsushima S, Ajiro M, Iida K, Chamoto K, Honjo T, Hagiwara M. Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci Transl Med. 2022 Nov 30;14(673):eabn6056. doi: 10.1126/scitranslmed.abn6056. Epub 2022 Nov 30. PMID: 36449604. 2: Ajiro M, Awaya T, Kim YJ, Iida K, Denawa M, Tanaka N, Kurosawa R, Matsushima S, Shibata S, Sakamoto T, Studer L, Krainer AR, Hagiwara M. Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat Commun. 2021 Jul 23;12(1):4507. doi: 10.1038/s41467-021-24705-5. Erratum in: Nat Commun. 2021 Oct 12;12(1):6039. doi: 10.1038/s41467-021-26287-8. PMID: 34301951; PMCID: PMC8302731. 3: Boussaad I, Obermaier CD, Hanss Z, Bobbili DR, Bolognin S, Glaab E, Wołyńska K, Weisschuh N, De Conti L, May C, Giesert F, Grossmann D, Lambert A, Kirchen S, Biryukov M, Burbulla LF, Massart F, Bohler J, Cruciani G, Schmid B, Kurz-Drexler A, May P, Duga S, Klein C, Schwamborn JC, Marcus K, Woitalla D, Vogt Weisenhorn DM, Wurst W, Baralle M, Krainc D, Gasser T, Wissinger B, Krüger R. A patient- based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. Sci Transl Med. 2020 Sep 9;12(560):eaau3960. doi: 10.1126/scitranslmed.aau3960. PMID: 32908004. 4: Yoshida M, Kataoka N, Miyauchi K, Ohe K, Iida K, Yoshida S, Nojima T, Okuno Y, Onogi H, Usui T, Takeuchi A, Hosoya T, Suzuki T, Hagiwara M. Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2764-9. doi: 10.1073/pnas.1415525112. Epub 2015 Feb 9. PMID: 25675486; PMCID: PMC4352824. 5: Aredes JE, Fassina NA, Macchi RL. Centric relation registration with intraoral central bearing on curved vs. flat plates with rim trays in edentulous patients. Acta Odontol Latinoam. 2021 Apr 1;34(1):35-42. English. doi: 10.54589/aol.34/1/035. PMID: 34137776. 6: Adzandeh AE, Awope J, Oviasu OI. A preliminary spatial analysis of diagnosed stroke disease in Osun state, Nigeria. Pan Afr Med J. 2016 Oct 3;25:63. doi: 10.11604/pamj.2016.25.63.5931. PMID: 28250887; PMCID: PMC5321153. 7: Aboyeji OS, Eigbokhan SF. Evaluations of groundwater contamination by leachates around Olusosun open dumpsite in Lagos metropolis, southwest Nigeria. J Environ Manage. 2016 Dec 1;183:333-341. doi: 10.1016/j.jenvman.2016.09.002. Epub 2016 Sep 5. PMID: 27609496. 8: Lara A, López JM, García-Chacón I, Morell M. Comparación de rectas patrón homóloga y heteróloga mediante TR-FIA, para la determinación de T4 total en rata [Comparison of homologous and heterologous standard curves using TR-FIA for the determination of total T4 in the rat]. Rev Esp Fisiol. 1992 Jun;48(2):83-6. Spanish. PMID: 1439084.